Search
Piroxicam
go.drugbank.com/drugs/DB00554ApprovedInvestigationalA cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea
Categories: Non COX-2 selective NSAIDS, Cytochrome P-450 SubstratesSynonyms: 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxidCeliprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnIt is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. … In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome.
Categories: Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor AgonistsSynonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylureaAtovaquone
go.drugbank.com/drugs/DB01117ApprovedInvestigationalAtovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Mixtures: Malarone 250 mg/100 mg Filmtabletten, Atovaquon/Proguanilhydrochlorid STADA 250 mg/100 mg FilmtablettenCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesCimetidine
go.drugbank.com/drugs/DB00501ApprovedInvestigationalA histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. … It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Mixtures: Cimetidine 5% / Ibuprofen 2% / Salicylic Acid 17%, Cimetidine 10% / Lidocaine 5% / Salicylic Acid 40%Categories: MATE 2 Inhibitors, MATE 2 SubstratesMycophenolate mofetil
go.drugbank.com/drugs/DB00688ApprovedInvestigational[A180826] The new semi-synthetic 2-morpholinoethyl ester of MPA was synthesized to avoid the gastrointestinal effects associated with the administration of MPA. … Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH).
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoateCefalotin
go.drugbank.com/drugs/DB00456ApprovedVet approvedWithdrawnCefalotin is a cephalosporin antibiotic.
Categories: Heterocyclic Compounds, 2-RingSynonyms: 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid, 7-(Thiophene-2-acetamido)cephalosporinOxymetazoline
go.drugbank.com/drugs/DB00935ApprovedInvestigationalOxymetazoline is an imidazole derivative and a potent, direct-acting alpha (α)-adrenergic agonist with affinity to both α<sub>1</sub>- and α<sub>2</sub>-adrenoceptors. … [A215542] Oxymetazoline is available in various formulations with a wide variety of clinical implications. The topical formulation of the drug is used to treat persistent facial redness in adults.
Synonyms: 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenolInternational brands: Dristan 12-Hour, Neo-Synephrine 12 Hour SprayAdapalene
go.drugbank.com/drugs/DB00210ApprovedInvestigationalOn December 8th, 2008, Galderma Labs gained FDA approval for Epiduo®, a 0.1% adapalene, 2.5% BPO combination gel.[L12873] … [A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution.
Mixtures: Adapalene 0.3% / Niacinamide 4%, Adapalene 0.3% / Benzoyl Peroxide 2.5% / Niacinamide 4%Synonyms: 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acidRilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigationalRilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients.[A31328] It is a diarylpyrimidine derivative. … [L1030] On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named
Mixtures: ODEFSEY® 200 MG - 25 MG - 25 MG TABLETAS RECUBIERTAS, ODEFSEY 200 MG/25 MG/25 MG FİLM KAPLI TABLET, 30 ADETCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesInavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational_PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. … [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical
Categories: Phosphoinositide-3 Kinase Inhibitors, Phosphatidylinositol-3-kinase (Pi3K) inhibitorsSynonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-